Our study revealed detectable amounts of IL-15 (>3 pg/mL) in some patients remaining in the UA stage, which might diminish the strength of the test we used for evaluating IL-15 as a biomarker for RA development. The gene discussed is IL15; the disease is rheumatoid arthritis.